-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF OCTOBER 22-28, 2023
October 20, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE FDA Event 10/22/2023 REGN 3.0 600 $808.47 Conference 10/22/2023 RVMD 37.7 33,800 $27.97 Conference 10/23/2023 HARP 52.4 307 $6.88 FDA Event 10/26/2023 CPRX 13.9 2,074 $12.80 WEEK: 10/22/2023 – 10/28/2023
-
Rocket Pharmaceuticals | Unlocking the Potential: RP-L201 and its FDA Designations – A Breakthrough in Pediatric Medicine
NASDAQ: RCKT Rocket Pharmaceuticals has achieved significant milestones with their groundbreaking therapy, RP-L201. The FDA has granted several prestigious designations to RP-L201, including Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric, Fast Track, and Orphan Drug designations. These designations highlight the immense potential of RP-L201 in treating pediatric patients and emphasize the urgent need for innovative…
-
Aquestive Therapeutics | FDA Acceptance of Libervant™ for Treatment of Seizure Clusters in Young Patients
NASDAQ: AQST The FDA has recently accepted the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film, aiming to tackle the treatment of seizure clusters in children between the ages of two and five. This development provides hope for young patients and their families who have pbeen struggling with the challenges of managing seizure clusters.…